facebook
Subscribe50$/product give away!


Submit an Article to Pharmacy HQ     
Please include the author's name, title, and citations.     

EYLEA- aflibercept injection, solution


  1. Patient Information
  2. Manufactured By:

Patient Information 

In the days following EYLEA administration, patients are at risk of developing endophthalmitis or retinal detachment. If the eye becomes red, sensitive to light, painful, or develops a change in vision, advise patients to seek immediate care from an ophthalmologist [seeWarnings and Precautions (5.1)].

Patients may experience temporary visual disturbances after an intravitreal injection with EYLEA and the associated eye examinations [seeAdverse Reactions (6)]. Advise patients not to drive or use machinery until visual function has recovered sufficiently.


REGENERON

Manufactured By: 

Regeneron Pharmaceuticals, Inc.

777 Old Saw Mill River Road

Tarrytown, NY 10591-6707

U.S. License Number 1760

EYLEA is a registered trademark of Regeneron Pharmaceuticals, Inc.

2019, Regeneron Pharmaceuticals, Inc.

All rights reserved.

Revised Date: August 2019

PRINCIPAL DISPLAY PANEL - 2 mg/0.05 mL Vial Carton

NDC 61755-005-02

EYLEA
(aflibercept) Injection
For Intravitreal Injection

2 mg/0.05 mL
Single-use Vial

Carton contents: Each EYLEA carton contains

  • one single-use, 3-mL, glass vial of EYLEA
  • one 19-gauge x 1 -inch, 5-micron, filter needle
    for withdrawal of the vial contents (filter needlenot
    to be used for intravitreal injection)
  • one 30-gauge x -inch needle for intravitreal injection
  • one 1-mL plastic syringe for administration
  • one package insert

Rx ONLY

PRINCIPAL DISPLAY PANEL - 2 mg/0.05 mL Vial Carton



Your use of this website constitutes your agreement to the terms and conditions linked below:
Terms and Conditions | Resources
2017 © Copyright PharmacyHQ.com. Questions?
Please contact: pharmacyhq.mail@gmail.com